Teva Pharmaceutical has partnered with Launch Therapeutics and secured $150 million in funding from Abingworth to accelerate the development of its innovative Dual-Action Asthma Rescue Inhaler (TEV-‘248).

Target Information

Teva Pharmaceutical Industries Ltd., a prominent global pharmaceutical leader, has announced a clinical collaboration agreement with Launch Therapeutics aimed at accelerating the development of its Dual-Action Asthma Rescue Inhaler (TEV-‘248). This innovative inhaler combines an Inhaled Corticosteroid (ICS) with a Short-Acting Beta-Agonist (SABA), positioning it to potentially transform asthma treatment for both adults and children.

TEV-‘248 is currently undergoing Phase 3 clinical trials, with an emphasis on demonstrating reduced severe exacerbations in asthma patients compared to traditional SABA treatments. This product addresses an important gap in asthma management, targeting both immediate symptoms and long-term inflammation, thereby improving overall patient outcomes.

Industry Overview in the United States

The asthma inhaler market in the United States represents a significant opportunity for innovation and growth. With over 25 million diagnosed asthma patients, there is a pressing need for more